drugset / Trial / NCT00206024

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

NCT00206024

Phase 4 Completed 330 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.

Timeline

Start
2004-11
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg

Indications